Abstract: Described herein are methods for preventing a relapse of cancer in a subject. The methods involve administering to the subject in need thereof a sulfated glycosaminoglycan or the pharmaceutically acceptable salt or ester thereof. In one aspect, the methods described herein prevent the growth or self-renewal of cancer stem cells in a subject. In another aspect, the methods described herein kill active or dormant cancer stem cells in a subject. The methods described herein can be used in combination with chemotherapy and/or radiation. The methods described herein are versatile with respect to preventing the relapse of a number of different cancers.

Abstract: The present disclosure may be embodied as a nurse call system. The nurse call system may include a patient hub. The patient hub may include a nurse call interface circuit configured to be in electronic communication with a nurse call patient station. The patient hub may further include a hub controller in electronic communication with the nurse call interface circuit. The nurse call system may further include a patient interaction device (“PID”). The PID may include a hub interconnect configured to be in electronic communication with the hub controller. The PID may further include a wireless communication link for receiving a PID software update. The PID software update may be a PID firmware update. The PID software update may be a PID operating system update.

Abstract: The present disclosure may be embodied as a nurse call system. The nurse call system may include a patient hub. The patient hub may include a nurse call interface circuit configured to be in electronic communication with a nurse call patient station. The patient hub may further include a hub controller in electronic communication with the nurse call interface circuit. The nurse call system may further include a patient interaction device (“PID”). The PID may include a hub interconnect configured to be in electronic communication with the hub controller. The PID may further include a wireless communication link for receiving a PID software update. The PID software update may be a PID firmware update. The PID software update may be a PID operating system update.

Abstract: Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Abstract: A system for monitoring an individual includes a processor and a LIDAR sensor in electronic communication with the processor. The processor is configured to receive a set of spatial data from the LIDAR sensor, calculate a first location of the individual relative to a support object based on the set of spatial data, and determine if the first location is at an alert location relative to the support object. In another aspect, a method for monitoring an individual includes receiving a first set of spatial data from a LIDAR sensor, calculating a first location of the individual relative to a support object based on the first set of spatial data, and determining if the first location is at an alert location relative to the support object.

Abstract: Described herein are methods for reducing or maintaining the size of a tumor in a subject, where the method involves exposing the tumor to ionizing radiation and administering to the subject a modified hyaluronan or a pharmaceutically acceptable salt or ester. The use of the modified hyaluronan enhances or potentiates the effect of ionizing radiation used in cancer treatment. Additionally, the methods described herein prevent or reduces tumor regrowth in the subject after exposing the tumor to ionizing radiation and administration of the modified hyaluronan to the subject.

Abstract: Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Abstract: The present disclosure may be embodied as a nurse call system. The nurse call system may include a patient hub. The patient hub may include a nurse call interface circuit configured to be in electronic communication with a nurse call patient station. The patient hub may further include a hub controller in electronic communication with the nurse call interface circuit. The nurse call system may further include a patient interaction device (“PID”). The PID may include a hub interconnect configured to be in electronic communication with the hub controller. The PID may further include a wireless communication link for receiving a PID software update. The PID software update may be a PID firmware update. The PID software update may be a PID operating system update.

Abstract: Described herein is the use of a methylated/sulfated hyaluronan, sulfated hyaluronan, or the pharmaceutically acceptable salt or ester thereof for the treatment of chronic rhinosinusitis.

Abstract: Provided herein is a composition and method for the treatment of a skin condition including actinic keratosis and cancer, the composition comprising O2-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yI]diazen-1-ium-1,2-diolate, (JS-K) in various formulations.

Abstract: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.

Abstract: Described herein are methods for treating inflammation in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.

Abstract: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.

Abstract: Described herein are methods for treating inflammation in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.

Abstract: Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.

Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compositions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.

Abstract: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such angiogenesis antagonists to treat end-stage liver disease and end-stage liver disease complications. The present application also describes the use of such angiogenesis antagonists to treat disorders of altered venous proliferation such hemorrhoids and varicose veins.

Abstract: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.

Abstract: Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.

Abstract: Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders.